Deutsche Bank Aktiengesellschaft Has Lowered Expectations for Albemarle (NYSE:ALB) Stock Price

Albemarle (NYSE:ALB) had its target price lowered by Deutsche Bank Aktiengesellschaft from $109.00 to $105.00 in a research note issued to investors on Wednesday.

Several other research firms also recently weighed in on ALB. Evercore ISI downgraded Albemarle from an “outperform” rating to an “inline” rating in a research report on Wednesday, February 5th. Robert W. Baird upped their price target on Albemarle from $79.00 to $103.00 and gave the stock a “neutral” rating in a research note on Wednesday, December 18th. Mizuho dropped their price target on Albemarle from $110.00 to $105.00 and set a “neutral” rating for the company in a research note on Tuesday, January 7th. KeyCorp dropped their price target on Albemarle from $132.00 to $127.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. Finally, Clarkson Capital started coverage on Albemarle in a research note on Tuesday, January 14th. They set a “buy” rating and a $112.00 price target for the company. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $114.24.

Albemarle Stock Performance

NYSE ALB opened at $76.57 on Wednesday. The business’s 50-day moving average price is $90.00 and its 200 day moving average price is $92.48. Albemarle has a twelve month low of $71.97 and a twelve month high of $143.19. The company has a market capitalization of $9.00 billion, a PE ratio of -4.57, a price-to-earnings-growth ratio of 3.43 and a beta of 1.59. The company has a current ratio of 2.44, a quick ratio of 1.58 and a debt-to-equity ratio of 0.43.

Albemarle (NYSE:ALB) last released its earnings results on Wednesday, February 12th. The specialty chemicals company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.49). Albemarle had a positive return on equity of 1.67% and a negative net margin of 28.80%. On average, research analysts predict that Albemarle will post -1.55 earnings per share for the current year.

Insider Buying and Selling at Albemarle

In other Albemarle news, CEO J Kent Masters sold 2,525 shares of the stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $101.12, for a total transaction of $255,328.00. Following the transaction, the chief executive officer now owns 73,747 shares of the company’s stock, valued at $7,457,296.64. This trade represents a 3.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.38% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Quarry LP lifted its holdings in Albemarle by 1,400.0% during the 3rd quarter. Quarry LP now owns 270 shares of the specialty chemicals company’s stock worth $26,000 after buying an additional 252 shares during the last quarter. Assetmark Inc. lifted its holdings in Albemarle by 340.6% during the 4th quarter. Assetmark Inc. now owns 304 shares of the specialty chemicals company’s stock worth $26,000 after buying an additional 235 shares during the last quarter. Trust Co. of Vermont lifted its holdings in Albemarle by 606.5% during the 4th quarter. Trust Co. of Vermont now owns 325 shares of the specialty chemicals company’s stock worth $28,000 after buying an additional 279 shares during the last quarter. Eastern Bank bought a new stake in shares of Albemarle in the 3rd quarter worth approximately $31,000. Finally, First Community Trust NA lifted its holdings in shares of Albemarle by 55.0% in the 4th quarter. First Community Trust NA now owns 400 shares of the specialty chemicals company’s stock worth $34,000 after purchasing an additional 142 shares during the last quarter. Institutional investors own 92.87% of the company’s stock.

About Albemarle

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services.